Sponsor: NRG
Sponsor Study ID: GY028
Study Title: A Phase IB and Randomized Phase II trial of Megestrol Acetate with or without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer
CTO #: 103895
NCT Number: NCT05538897
Phase: I/II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Other Female Genital
Study Objectives: Determine the toxicity of ipatasertib in combination with megestrol acetate in women with metastatic grade 1-2 endometrioid endometrial cancer and establish the recommended phase II dose. Compare the progression free survival of the combination of ipatasertib with megestrol acetate to megestrol acetate alone among women with metastatic grade 1-2 emdometrioid adenocarcinoma of the endometrium. Compare the toxicity of the combination of ipatasertib with megestrol acetate to megestrol acetate alone.